Samuel D. Stanton

Samuel D. Stanton

Auto-generated profile, based on publicly available information

Samuel D. Stanton

Genentech

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
NFNathan C. Frey
Nathan C. Frey
IHIsidro Hötzel
Isidro Hötzel
SSSamuel D. Stanton
Samuel D. Stanton
RKRyan L Kelly
Ryan L Kelly
RARobert G. Alberstein
Robert G. Alberstein
CSChristoph Spiess
Christoph Spiess
Therapeutic antibody design is a complex multi-property optimization problem with substantial promise for improvement with the application of machine-learning methods. Towards realizing that promise, we introduce “Lab-in-the-loop,” a new approach that orchestrates state-of-the-art repertoire mining methods, generative machine learning models, multi-task property predictors, active learning ranking and selection, and in vitro experimentation in a semi-autonomous, iterative optimization loop. By automating the design of antibody variants, property prediction, ranking and selection of designs to assay in the lab, and ingestion of in vitro data, we enable an end-to-end approach to developing computationally-informed therapeutic antibody design pipelines. We apply lab-in-the-loop to eleven seed antibodies obtained via animal immunization with four clinically relevant antigen targets: EGFR, IL-6, HER2, and OSM. Over 1,800 unique antibody variants are tested throughout four rounds of iterative optimization identifying 3–100× better binding variants for all targets and 10/11 seeds, with the best binders exceeding 100 pM affinity, demonstrating a process by which end-to-end machine learning can be developed for therapeutic antibody development.

13 November 2025 in bioRxiv
Verified
Preprint
Open access
ISImee Sinha
Imee Sinha
SSSamuel Stanton
Samuel Stanton
SLStephen Lillington
Stephen Lillington
SRSarah A. Robinson
Sarah A. Robinson
SNSantrupti Nerli
Santrupti Nerli
SKSimon Kelow
Simon Kelow
Antibody lead optimization methods seek to enhance a lead candidate's therapeutic properties through targeted sequence mutation. However, the mutations introduced during this process can inadvertently induce structural changes that disrupt binding, particularly by altering CDR loop conformations which destabilize CDR-target binding interactions. To address this, we present ConformAb, a guided discrete diffusion model for designing antibody sequences that explicitly conform to the CDR canonical conformation of the lead. With seed sequences as the starting point, we show that our method is capable of generating 3-5× better binders that conform to the same CDR backbone structure in a one-shot design setup, and in some cases, binders with better affinity than seed repertoire picks without any target-specific data included in training. Across the targets tested, ConformAb demonstrated binding rates ranging from 15-60% in wet lab experiments, a result obtained using fewer than 100 designs for each target. ConformAb offers a unique one-shot approach for antibody lead optimization in data-scarce scenarios where experimental/repertoire data cannot be leveraged for model training.